Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Merck KGaA is in advanced talks to buy US cancer and rare diseases drugmaker SpringWorks Therapeutics Inc., according to a ...

Seven of 10 people with measles in Texas are hospitalized for a disease that was considered eliminated in 2000. Kennedy has ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

Merck KGaA is in advanced talks to acquire SpringWorks Therapeutics, aiming to expand its cancer treatment pipeline. While no binding agreement exists yet, a potential deal is seen as strategically ...

Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms ...